The test MRSA and MSSA directly from blood culture samples in about one hour, compared to between 48 and 72 hours with other methods, the company said.
A new microbiome analysis uncovered cancer type-specific bacterial community features, along with intracellular bacteria in tumor and associated immune cells.
Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.
The team will present the results to the US Food and Drug Administration as part of a 510(k) application in order to commercialize the technology with Biofluidica.
The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.
